Boehringer Ingelheim GMBH reported 56.1% currency-adjusted growth in its diabetes business in 2016, and from 2017 the early lead in the use of diabetes medication for cardiovascular indications that it and partner Eli Lilly & Co. have established looks likely to help drive continued expansion.
The family-owned German company revealed that total global sales of the SGLT-2 inhibitor Jardiance (empagliflozin) were €433m in 2016, with...








